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Abstract 14 
ILC2s were originally identified as IL-5 and IL-13 secreting ‘natural helper cells’ present 15 
within the fat associated lymphoid clusters of the mesenteries in both mouse and man. The 16 
presence of ILCs in adipose tissue has more recently expanded to include all ILC groups. Since 17 
their initial discovery, our knowledge of these cells and their role in adipose immune responses 18 
has expanded significantly. In this review we summarise the current literature on the role that 19 
ILC2s play in orchestrating adipose tissue function in both lean and obese states. We go on to 20 
address new data detailing interactions of adipose ILCs with innate like B-cells (IBC) and 21 
discuss how this interaction results in localised protection of mucosal sites during infection and 22 
inflammation via the production of innate antibodies.  23 
 24 
Introduction 25 
Innate lymphoid cells are the newest kids on the block in terms of innate immune cell function, 26 
however the previous 8 years have revealed a wealth of information on these previously 27 
enigmatic lymphocyte like cells. In a non-activated state, ILCs possess lymphocyte 28 
morphology but lack the expression of surface markers used to define other immune cell 29 
populations. ILCs are thus described as ‘lineage negative’. Non-cytotoxic ILCs are currently 30 
segregated into three transcriptionally defined groups that mirror the four major T-helper cell 31 
subsets. Tbet dependent ILC1s which secrete IFNγ and TNFα, GATA3 dependent ILC2s which 32 
secrete IL-5/IL-13 (and can secrete IL-10(Seehus, Kadavallore et al. 2017)) , RORγt dependent 33 
ILC3s which secrete IL-17A/IL-22 and include a population of Lymphoid tissue inducer (LTi) 34 
cells which are critical for secondary lymphoid organ development (Artis and Spits 2015) and 35 
finally, Id3 dependent ILCregs which produce IL-10 and require autocrine TGF-β1(Wang, Xia 36 
et al. 2017). In addition to these non-cytotoxic cell types, are the classical cytotoxic NK cells 37 
that are important for protection against viruses and cancer. Although ILCs were first described 38 
as natural helper cells (ILC2) in the fat associated lymphoid clusters of the mesenteries where 39 
they support antibody responses, their presence and importance has since been extended to the 40 
whole adipose organ with ILCs having been reported in most fat depots. ILCs are now 41 
considered as key regulators of adipose tissue function. IBCs are B cells with ‘innate like’ 42 
properties; they have a poly-specific B-cell receptor repertoire and rapidly produce polyclonal 43 
IgM in response to both self and microbial antigens(Jackson-Jones and Benezech 2018). Here 44 
we will discuss 1) the central regulatory role of ILC2 in the regulation of adipose tissue 45 
homeostasis and 2) the key role of ILCs in activation of the IBC compartment during infection 46 
at mucosal sites.  47 
 48 
ILC2s are critical regulators of type 2 immune cells to maintain white adipose tissue 49 
homeostasis  50 
 2 
Recently, it has become apparent that type 2 immune cells play a critical role in the 1 
maintenance of homeostasis in lean, healthy adipose tissue and that ILC2 are central regulators 2 
of this function. Type 2 immune cells including ILC2, T regulatory cells (Treg), T-helper type 3 
2 cells (Th2), Eosinophils, mast cells and M2 macrophages are prevalent in healthy adipose 4 
tissue where they contribute to adipose tissue remodelling, counteracting the inflammatory 5 
effect of obesity and inducing browning of white adipose tissue (Odegaard and Chawla 2015, 6 
Villarroya, Cereijo et al. 2018). Here, we will concentrate on the role of ILC2 in orchestrating 7 
the function of type 2 immune cells in adipose tissue.   8 
 9 
ILC2s and immune homeostasis in white adipose tissue  10 
ILC2s are present within visceral adipose tissue (VAT), where they are the predominant 11 
producers of IL-5 and IL-13 at homeostasis and following prolonged exposure to IL-33 or 12 
helminth infection (Hams, Locksley et al. 2013, Molofsky, Nussbaum et al. 2013). Th2 cells 13 
remain a minor population of IL-5 and IL-13 producing cells within the VAT even during 14 
helminth infection (Molofsky, Nussbaum et al. 2013). In lean adipose tissue, IL-33 drives the 15 
recruitment and/or proliferation of ILC2 but the cellular origin of IL-33 and the mechanisms 16 
leading to its secretion at homeostasis remains poorly understood. While we reported that 17 
Gp38+ stromal cells of fat associated lymphoid clusters (FALCs) express high levels of IL-33, 18 
others showed that IL-33 is also expressed by Gp38+ fibroblasts, Cadherin-11+ mesenchymal 19 
cells, or endothelial cells of the stromal vascular fraction of adipose tissue (Kolodin, van 20 
Panhuys et al. 2015, Molofsky, Van Gool et al. 2015, Jackson-Jones, Duncan et al. 2016, 21 
Kohlgruber, Gal-Oz et al. 2018). It is likely that the relevant source of IL-33 in adipose tissue 22 
is context dependent and further work is needed to elucidate the mechanism of IL-33 action in 23 
adipose tissue. Tissue ILC2s are key producers of systemic IL-5 required for homeostatic 24 
eosinophil maintenance (Nussbaum, Van Dyken et al. 2013). In adipose tissue, secretion of IL-25 
5 by ILC2 is essential for the recruitment and maintenance of eosinophils (Molofsky, 26 
Nussbaum et al. 2013) and is dependent on IL-33 (Molofsky, Nussbaum et al. 2013) (Figure 27 
1).  Secretion of IL-13 and IL-4 by ILC2 and eosinophils is critical for the maintenance of 28 
alternatively activated or M2-like adipose tissue macrophages and glucose homeostasis (Wu, 29 
Molofsky et al. 2011, Molofsky, Nussbaum et al. 2013).   The precise phenotype and origin of 30 
these macrophages is not known. Interestingly IL-33 has been shown to be competent to induce 31 
macrophage proliferation independently of IL-4Rα expression in other non-adipose 32 
macrophages populations{Jackson-Jones, 2016 #3) (Jackson-Jones, Ruckerl et al. 2016) and 33 
whether IL-33 can directly activate adipose tissue macrophages remains to be investigated.  34 
 35 
Pioneering work by the group of Diane Mathis demonstrated the existence of a unique  subset 36 
of GATA-3+ PPARγ+ regulatory T cells in adipose tissue important for preventing insulin 37 
resistance(Feuerer, Herrero et al. 2009, Cipolletta, Feuerer et al. 2012). Regulatory T cells in 38 
adipose tissue express the IL-33 receptor ST2 and require IL-33 for their maintenance 39 
(Vasanthakumar, Moro et al. 2015). Additionally, expression of ICOSL by adipose tissue ILC2 40 
provides additional signalling through ICOS in regulatory T cells for their accumulation within 41 
VAT (Molofsky, Van Gool et al. 2015). Halim et al elegantly advance these finding by showing 42 
that in the absence of ILC2s or specifically the absence of OX40L expression by ILC2s there 43 
is a significant deficit in the number of GATA3+ T-regulatory cells within the perigonadal 44 
adipose tissue following IL-33 delivery(Halim, Rana et al. 2018). 45 
 46 
ILC2s and adipose tissue browning 47 
Brown and beige adipose tissue are fat depots specialised in the dissipation of energy for the 48 
production of heat. While brown adipose tissue is mostly found in infants and regresses with 49 
age, white adipose tissue can undergo “browning” to form beige adipose tissue, expressing the 50 
 3 
thermogenic protein Ucp1 during exposure to cold (Poher, Altirriba et al. 2015). Two distinct 1 
mechanisms involving ILC2s have been implicated in the browning of adipose tissue.  2 
Mechanism one relies on the IL-33 dependent induction of methionine-enkephalin peptide 3 
release from ILC2s that acts directly on adipocytes to upregulate UCP-1 and induce beiging 4 
(Brestoff, Kim et al. 2015). The second published mechanism involves pharmacologic 5 
expansion and activation of ILC2 with IL-33 in thermoneutral mice which induces the 6 
proliferation of adipocytes and their differentiation into beige adipocytes (Lee, Odegaard et al. 7 
2015). This is dependent on the release of IL-4 and IL-13 by ILC2 and the direct activation of 8 
adipocyte precursor cells via the IL-4Rα (Lee, Odegaard et al. 2015). ILC2 may also be 9 
important for the activation of eosinophils during acute cold exposure and the secretion of IL-10 
4/13, which have been reported to induce browning through activation of alternatively 11 
activated macrophage production of catecholamines (Qiu, Nguyen et al. 2014). However, the 12 
mechanisms leading to secretion of IL-33 upon cold exposure were not elucidated.  The 13 
production of catecholamines by alternatively activated macrophages is controversial with a 14 
recent report stating that alternatively activated macrophages do not produce catecholamines 15 
and are thus unlikely to have a direct role in adipocyte metabolism or adaptive thermogenesis 16 
(Fischer, Ruiz et al. 2017).  17 
 18 
Is there a link between the gut mucosa and the metabolic regulatory function of ILC2 in adipose 19 
tissue?  20 
In the small intestine, the release of IL-5 and IL-13 by ILC2 is increased by food intake, leading 21 
to fluctuation in the levels of circulating eosinophils during the day (Nussbaum, Van Dyken et 22 
al. 2013). It would be interesting to know if the secretion of IL-5 and IL-13 or other important 23 
mediators such as methionine-enkephalin peptides by adipose tissue ILC2s fluctuates with food 24 
intake, thus allowing the synchronisation of adipose tissue function with food intake via 25 
immune regulation. 26 
 27 
A link between adipose tissue ILC2s and metabolic dysfunction 28 
During obesity the number of ILC2s decreases in adipose tissue both in mouse and human, 29 
leading to decrease in overall Type-2 immunity and increased inflammation in adipose tissue. 30 
Importantly, the loss of ILC2 in obesity can be reversed by IL-33 injection in obese mice 31 
restoring glucose tolerance and insulin sensitivity.  However, the mechanisms leading to the 32 
loss of ILC2 during obesity are not well understood. Interestingly, a population of ILC1s 33 
expand in the adipose tissue during diet-induced obesity and produce IFN-γ in response to IL-34 
12, contributing to inflammation and insulin resistance (O'Sullivan, Rapp et al. 2016). IFN-γ 35 
has an antagonistic effect on ILC2 (Molofsky, Van Gool et al. 2015) which may be responsible 36 
for the loss of ILC2 during obesity. It is also possible that IFNγ and or IL-12 drives the 37 
conversion of ILC2 towards ILC1 during diet-induced obesity, as described in response to IL-38 
12(Lim, Menegatti et al. 2016). In addition, upregulation of PD-1 expression on ILC2 and its 39 
engagement via PD-L1hi M1 macrophages has recently been described to inhibit the protective 40 
function of ILC2s during obesity. Within obese adipose, increased PD-1 expression on ILC2s 41 
was dependent on TNFα and IL-33 (Oldenhove, Boucquey et al. 2018).  42 
 43 
In the second half of this mini-review, the original role of ILCs in the initiation of local immune 44 
function in FALCs is discussed and extended to include the newly described pleural FALCs 45 
(Elewa, Ichii et al. 2014, Benezech, Luu et al. 2015, Jackson-Jones, Duncan et al. 2016); finally 46 
we discuss the interaction between ILC2s, IBCs and IgM during atherosclerosis.   47 
 48 
Fat Associated Lymphoid Cluster function in mucosal defence  49 
 4 
The peritoneal and pleural cavities, primarily considered as sites of macrophage (Bain and 1 
Jenkins 2018) and B1 cell residence represent compartments that demarcate, contain and 2 
protect the boundaries between three major mucosal sites directly exposed to environmental 3 
antigens; namely the lungs, the intestines and the reproductive tract (of females)(Figure 2). 4 
Immune protection within the body cavities is co-ordinated by small, inducible lymphoid 5 
clusters found within specialised small adipose tissues (the mediastinum, pericardium, 6 
mesenteries and omentum). Initially described as ‘milky-spots’ within the omentum(Dickinson 7 
1906) these inducible structures were rebranded in 2010 as Fat Associated Lymphoid Clusters 8 
or FALCs (Moro, Yamada et al. 2010). FALCs are local hubs that are important for providing 9 
a second line of defence between the mucosal surfaces and a systemic immune response, 10 
working to compartmentalise antibody mediated immune responses within body cavities. 11 
Evidence supporting FALC orchestration of antibody responses within the body cavities is 12 
mounting, with multiple reports linking FALCs to the initiation of T-independent and T-13 
dependent immune responses (Rangel-Moreno, Moyron-Quiroz et al. 2009, Moro, Yamada et 14 
al. 2010, Benezech, Luu et al. 2015, Jones, Racine et al. 2015, Jackson-Jones, Duncan et al. 15 
2016).  16 
 17 
FALCs, ILCs and the initiation of innate like B cell responses 18 
Intestinal barrier functions  19 
FALCs were identified as immune cell aggregates within the mesenteries, that were enriched 20 
in lineage negative, c-Kit+, Sca-1+ cells; these cells are now known as ILC2s(Moro, Yamada et 21 
al. 2010, Neill, Wong et al. 2010, Price, Liang et al. 2010). ILC2s are potent producers of IL-22 
5 and IL-13; detectable levels of both cytokines are induced in the peritoneal lavage of Rag2-/- 23 
mice which do not have mature T or B cells, but are absent from γc-/-Rag2-/- following infection 24 
with the tissue migrating parasite Nippostrongylus brasiliensis (Moro, Yamada et al. 2010). 25 
This result highlighted the potency of common-gamma chain receptor dependent innate 26 
immune cells for the initiation of immune responses within the peritoneal cavity in the context 27 
of intestinal worm infection. IL-5 is a critical growth factor for B1 B cells (Erickson, Foy et al. 28 
2001); Moro and colleagues showed, using elegant in vivo transfers and in vitro co-cultures of 29 
ILC2 with peritoneal B-cells in the presence or absence of a blocking antibody against IL-5, 30 
that ILC2s provide support for B1 cell self-renewal (Moro, Yamada et al. 2010). ILC2s isolated 31 
from mesenteric FALCs were also shown to be competent for the induction of IgA secretion 32 
by peritoneal B cells in vitro (Moro, Yamada et al. 2010). Peritoneal B1 cells have been shown 33 
to migrate to the intestinal lamina propria in order to secrete IgA (Fagarasan, Kawamoto et al. 34 
2010, Baumgarth 2011). In addition to the conventional ‘Type-2’ cytokines described above, 35 
ILC2 have also been shown to secrete IL-6 (Mjosberg, Bernink et al. 2012)(Salimi, Barlow et 36 
al. 2013). As IL-6 has been described to induce antibody production by B-cells, as well as act 37 
as a growth factor for plasmablasts (Jego, Bataille et al. 2001)  and contribute to the regulation 38 
of T follicular helper cells (Eto, Lao et al. 2011), it is plausible that ILC2 secretion of this 39 
cytokine locally modifies FALC B-cell function; a hypothesis that warrants further 40 
experimental investigation to confirm. Contrary to secondary organs, the development of 41 
FALCs is not dependent on ILC3 as shown by the normal development and composition of 42 
FALCs in Rorc-/- mice (Benezech, Luu et al. 2015). However, studies in germ free mice 43 
revealed that the number of FALCs forming in the mesenteries is decreased indicating that 44 
factors derived from the commensal flora are important to drive the formation of FALCs. 45 
ILC3s are an important innate source of GM-CSF, a cytokine required for the induction of IgM 46 
by innate response activator (IRA) B cells (Rauch, Chudnovskiy et al. 2012). Competency to 47 
support IgA secretion by B1 was also reported for peritoneal macrophages, which had been 48 
exposed to omentum culture supernatant (Okabe and Medzhitov 2014). Given the almost 49 
certain presence of ILC derived factors within the omental culture supernatant, it is hard to 50 
 5 
know what component of the IgA secretion mediated by peritoneal macrophages is in part 1 
dependent upon ILCs. A thorough characterisation of the ILC occupation of the murine 2 
omentum has not been carried out; however a recent report characterised the presence of ILCs 3 
in multiple human tissues including detailing the presence of ILC1 like cells within the 4 
omentum (Simoni, Fehlings et al. 2017). 5 
 6 
Pulmonary barrier functions  7 
IgM is a large antibody and as such secretion of IgM into the circulation does not guarantee its 8 
presence at tissue sites where it is required. In the global absence of the IL-33R ST2, the 9 
secretion of IgM from FALCs within the pleural cavity is ablated (Jackson-Jones, Duncan et 10 
al. 2016). This is not a direct effect on the B-cells as co-transfer of IL-33R sufficient and 11 
deficient B-cells resulted in comparable induction of B-cell activation following Alternaria 12 
alternata delivery. Utilising blocking antibodies against IL-5 delivered directly into the pleural 13 
space, we concluded that the IL-33 was acting via an IL-5 producing intermediate population 14 
of cells. ILC2s were the only cells found to be expressing IL-5 within FALCs of the pleural 15 
cavity during type-2 inflammation (Jackson-Jones, Duncan et al. 2016). Thus, the presence of 16 
IgM secreting B-cells within FALCs in the context of type-2 inflammation is assumed to 17 
depend upon IL-5 secretion from IL-33 activated ILC2s. The link between ILC2 and antibody 18 
production within the thoracic cavity was also made by Drake et al 2016 who showed that in 19 
vitro culture of lung derived ILCs with splenic B cells resulted in antibody production (Drake, 20 
Iijima et al. 2016). However, as there are fewer B-cells within the lungs and because fluid phase 21 
B cells isolated from the pleural space do no secrete antibodies, it is likely that pleural FALCs 22 
are the sites where the ILC/B cell interactions take place in the thoracic cavity. In support of a 23 
tight immune crosstalk between lung and pleural space is a report showing that delivery of  24 
GM-CSF secreting IRA B cells into the pleural space mediates protection from pneumonia 25 
(Weber, Chousterman et al. 2014). Neither the role of FALCs in the activation of the transferred 26 
IRA B cells nor the requirement for lung or FALC resident ILCs in this process was 27 
investigated. This study serves to further highlights the crosstalk which occurs between 28 
mucosal tissues and their associated serous cavities. 29 
 30 
Is FALC derived IgM Atheroprotective?  31 
Innate like B-cells (IBCs) can be both protective and pathogenic in atherosclerosis. 32 
Recognition of oxidation specific epitopes on low density lipoproteins (LDL) (Binder, 33 
Hartvigsen et al. 2004) by natural IgM plays a protective role in atherosclerosis and clinical 34 
studies show that lower levels of IgM correlates with increased risk of cardiovascular diseases. 35 
The production of atheroprotective IgM by IBCs is dependent on IL-33 (Miller, Xu et al. 2008), 36 
IL-5 and IL-5 producing ILC2 (Perry, Oldham et al. 2013, Newland, Mohanta et al. 2017), a 37 
signaling loop that is active in FALCs (Jackson-Jones, Duncan et al. 2016). Importantly, it has 38 
been shown that the number of FALCs in the para-aortic adipose of ApoE-/- mice increases in 39 
the vicinity of atherosclerotic lesions (Newland, Mohanta et al. 2017) and that they contain 40 
IBC producing atheroprotective IgM (Srikakulapu, Upadhye et al. 2017). This suggests that 41 
ILC2 regulation of local IgM secretion by FALC IBCs could be key to IBC mediated 42 
atheroprotection and that loss of ILC2 during the development of obesity could contribute to 43 
accelerated atherosclerosis. 44 
 45 
Summary  46 
Since their initial discovery 8 years ago, ILC2s have emerged as major regulators of type-2 47 
immunity in adipose tissue where they co-ordinate eosinophil, macrophage, adipocyte and IBC 48 
function. FALCs are specialised hubs that act as a second line of immune defence sitting behind 49 
the mucosal frontline. Key to the initiation of a FALC response is the local secretion of 50 
 6 
cytokines by FALC resident ILCs, which kick-start the ensuing immune response following 1 
detection of a danger signal (eg IL-33). 2 
 3 
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Figure Legends 13 
Figure 1. The ILC2 driven interactions that regulate immune adipose function. In the lean state 14 
(centre; cream) IL-33 action (green arrows) signals to both T-regulatory cells (Treg) and ILC2 15 
resulting in regulated Type-2 immunity via the activity of secreted and membrane bound type-16 
2 signals (blue arrows); this response is amplified in the presence of lower ambient living 17 
temperature and during infancy and can result in browning thermogenesis within adipose tissue 18 
(Left; brown). Type-2 signals that can control browning are shown (brown arrows). In the 19 
obese state (right; pink) Inflammation mediated by type-1 signals (red arrows) promotes the 20 
activation of ILC1 and the inhibition of ILC2 which results in inhibition of M2 and expansion 21 
of the M1 macrophage population which contribute to the development of insulin resistance. 22 
During Type-2 inflammation within the lung or gut, ILC2 containing FALCs (Black circles) 23 
expand; IL-33 produced by stromal cells (green arrow) increases IL-5 secretion (blue arrow) 24 
from ILC2 which induces innate like B cell (IBC) proliferation and secretion of IgM. (MetEnk= 25 
methionine-enkephalin peptides,  NE= norepinephrine, Eos = Eosinophils, IBC = Innate Like 26 
B cell, M1/M2 = M1 or M2 macrophage)  27 
 28 
Figure 2. Compartmentalized protection of mucosal sites by fat associated lymphoid clusters 29 
within body cavities. Within the pleural cavity, protection from/regulation of, microbiota, 30 
infection, inflammation and damage is mediated by inducible FALCs within the pericardium 31 
(green) and mediastinum (orange). Within the peritoneal cavity, protection from/regulation of 32 
microbiota, infection, inflammation and damage is mediated by FALCs within the omentum 33 
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Figure 1. The ILC2 driven interactions that regulate immune adipose function. In the lean state
(centre; cream) IL-33 action (green arrows) signals to both T-regulatory cells (Treg) and ILC2
resulting in regulated Type-2 immunity via the activity of secreted and membrane bound type-2
signals (blue arrows); this response is amplified in the presence of lower ambient living
temperature and during infancy and can result in browning thermogenesis within adipose tissue
(Left; brown). Type-2 signals that can control browning are shown (brown arrows). In the obese
state (right; pink) Inflammation mediated by type-1 signals (red arrows) promotes the activation of
ILC1 and the inhibition of ILC2 which results in inhibition of M2 and expansion of the M1
macrophage population which contribute to the development of insulin resistance. During Type-2
inflammation within the lung or gut, ILC2 containing FALCs (Black circles) expand; IL-33
produced by stromal cells (green arrow) increases IL-5 secretion (blue arrow) from ILC2 which
induces innate like B cell (IBC) proliferation and secretion of IgM. (MetEnk= methionine-
enkephalin peptides, NE= norepinephrine, Eos = Eosinophils, IBC = Innate Like B cell, M1/M2 =
M1 or M2 macrophage)
Figure 2. Compartmentalized protection of mucosal sites by fat associated lymphoid clusters
within body cavities. Within the pleural cavity, protection from/regulation of, microbiota,
infection, inflammation and damage is mediated by inducible FALCs within the pericardium
(green) and mediastinum (orange). Within the peritoneal cavity, protection from/regulation of
microbiota, infection, inflammation and damage is mediated by FALCs within the omentum
(purple) and mesenteries (pink) m= mediastinal, PeriC= pericardial, om=omental,
mes=mesenteric
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